PK68 is an effective and selective inhibitor of type II receptor-interacting kinase 1 (RIPK1, IC50 = 90?nM). PK68 can be used for research on the treatment of inflammatory disorders and cancer metastasis.

IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).IGF-I (24-41) (TFA) is amino acids 24 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

Buddlejasaponin IVb(200 uM) can shorten thrombin time (TT) by 20.6 %, suggests that it has hemostasis efficacy.